Dublin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- The "mRNA Synthesis & Manufacturing Market by Product (Consumables [Transcription, Purification, Analysis & Characterization], Instrument), Service (Synthesis ...
Dublin, April 15, 2025 (GLOBE NEWSWIRE) -- The "MRNA Synthesis & Manufacturing Market by Product (Consumables [Transcription, Purification, Analysis & Characterization], Instrument), Service ...
The "mRNA Therapeutics Contract Development & Manufacturing Organization - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for mRNA ...
The market is expanding rapidly due to factors such as the development of mRNA-based vaccines and expanded applications such as cancer immunotherapies. Furthermore, improvements in mRNA synthesis ...
アクセリード株式会社（代表取締役社長：藤澤朋行／以下、アクセリード）は、合弁会社「株式会社ARCALIS」（代表取締役社長：藤澤朋行／以下、アルカリス）をArcturus Therapeutics Holdings, Inc.（President & CEO：Joseph E. Payne, NASDAQ：ARCT／以下、アークトゥルス）と ...
As mRNA therapeutics expand into cancer vaccines, cell therapies and beyond, manufacturing high-quality mRNA with minimal byproducts is more critical than ever. This poster explores how a novel ...
The success of the mRNA-based vaccines against SARS-CoV-2 merely hint at the healthcare implications of mRNA technology. More mRNA-based vaccines are in the works, as are mRNA-based therapeutics for ...
CAPE TOWN, WESTERN CAPE , SOUTH AFRICA, November 21, 2024 /EINPresswire.com/ -- The groundbreaking mRNA Technology Transfer Programme, launched in 2021, has gone from ...
アクセリード、mRNA医薬品CDMO合弁会社「ARCALIS」を設立 アクセリード株式会社（代表取締役社長：藤澤朋行／以下、アクセリード）は、合弁会社「株式会社ARCALIS」（代表取締役社長：藤澤朋行／以下、アルカリス）をArcturus Therapeutics Holdings, Inc.（President & CEO ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する
フィードバック